Urolithin A did not improve blood-vessel function in a four-week trial of 50 adults with obesity

Urolithin A has one of the cleaner stories in the supplement world: gut bacteria make it from compounds in pomegranates and walnuts, it switches on mitophagy — the cell's system for clearing out damaged mitochondria — and human trials have reported shifts in mitochondrial biomarkers and some muscle measures. A randomized clinical trial published October 9, 2026 in JAMA Network Open (da Costa Pinaffi-Langley, Yabluchanskiy and colleagues, University of Oklahoma) tested a specific hope: that it would also help blood vessels work better in middle-aged adults with obesity, whose vessels are under metabolic strain.

On its primary question, the answer was no.

What did the trial test?

The trial randomized 50 middle-aged adults with obesity to urolithin A at doses used in published studies — 1,000 mg daily — or placebo for four weeks. The main outcome was peripheral endothelial function: how well arteries widen and small vessels deliver blood flow, measured with standard vascular tests including brachial artery flow-mediated dilation.

What happened?

After four weeks, endothelial function in the urolithin A group was no significantly different from placebo — not on flow-mediated dilation and not on the other peripheral measures. The supplement was well tolerated and the trial was feasible to run, but tolerability is not efficacy.

One secondary measure did move: during a mental task, the brain's blood-flow (cerebrovascular hemodynamic) response was greater with urolithin A. Performance on the cognitive task itself did not improve. The authors frame the brain finding as a reason for follow-up research — longer trials (they suggest at least 12 weeks), with a more balanced mix of participants — not as a demonstrated benefit.

How should supplement buyers read this?

As a calibration point. A null result on a pre-specified primary outcome in a randomized trial outweighs biomarker shifts and mechanism stories, however elegant the mitophagy rationale is. Four weeks is short and 50 people is small, so the trial cannot rule out subtler or slower effects — but the burden of proof sits with the claim, and for blood-vessel function in this population, the claim did not meet it.

There is also no established dose of urolithin A for preventing cognitive decline, cardiovascular disease, or aging itself. Doses used in published studies are research doses. Readers weighing the supplement should price it as an unproven experiment, not a validated vascular or brain intervention.

Where the evidence stands

• Established: Urolithin A is a gut-derived metabolite that stimulates mitophagy in preclinical work; earlier human trials reported mitochondrial biomarker changes and selected muscle measures, without establishing disease-prevention benefits.
• Preliminary: In this 50-person, 4-week randomized trial (1,000 mg/day), urolithin A did not significantly improve peripheral endothelial function versus placebo; a secondary task-evoked cerebrovascular response was larger, with no improvement in cognitive performance.
• Absent: Evidence that urolithin A prevents dementia, cardiovascular disease, or biological aging; any validated clinical dose for those purposes; longer and larger trials of the cerebrovascular signal.